4525-70-6

Basic information

• Product Name: Propanedioic acid, phenoxy-, diethyl ester
• Synonyms: Phenoxymalonsaeure-diaethylester;2-phenoxypropanedioicacid diethylester;2-Phenoxymalonsaeurediethylester;phenoxy-malonic acid diethyl ester;Phenoxy-malonsaeure-diaethylester;diethyl phenoxymalonate
• CAS NO: 4525-70-6
• Molecular Formula: C13H16O5
• Molecular Weight: 252.267
• Mol File: 4525-70-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 52-53 °C
• Boiling Point: 155-157 °C(Press: 5 Torr)
• Density: 1.147±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Propanedioic acid, phenoxy-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, phenoxy-, diethyl ester(4525-70-6)
• EPA Substance Registry System: Propanedioic acid, phenoxy-, diethyl ester(4525-70-6)

Safety Data

• Hazardous Substances Data: 4525-70-6(Hazardous Substances Data)

Upstream product

• 139-02-6 sodium phenoxide 
• 685-87-0 Diethyl 2-bromomalonate 
• 108-95-2 phenol 
• 14064-10-9 diethyl 2-chloromalonate 
• 2555-49-9 phenoxyacetic acid ethyl ester 
• 412300-23-3 phenoxy-oxalacetic acid diethyl ester 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 
• 56-23-5 tetrachloromethane 

Downstream Products

• 874533-50-3 (2-cyano-ethyl)-phenoxy-malonic acid diethyl ester 
• 5800-08-8 2-phenoxypropane-1,3-diol 
• 31593-62-1 Phenoxybrommalonsaeurediaethylester 
• 170914-16-6 4-Hydroxy-3-phenoxy-6-phenyl-2H-pyran-2-one 
• 873392-23-5 3-phenoxy-2-oxo-piperidine-3-carboxylic acid ethyl ester 
• 110167-33-4 4-benzyl-6-phenoxy-1,4-oxazepane oxalate 
• 110167-29-8 2-(Benzoylamino-methyl)-2-phenoxy-malonic acid 
• 110167-32-3 4-benzyl-6-phenoxy-1,4-oxazepan-3-one 
• 110167-30-1 4-benzoyl-2-phenoxy-β-alanine 
• 110167-31-2 3-benzylamino-2-phenoxypropan-1-ol 
• 118644-49-8 N-(2,6-Dichlorbenzoyl)-N'-(4,6-dichlor-5-phenoxypyrimidin-2-yl)harnstoff 
• 118644-42-1 N-(2,6-Difluorbenzoyl)-N'-(4,6-dichlor-5-phenoxypyrimidin-2-yl)harnstoff 
• 118643-84-8 2-Acetamido-4,6-dihydroxy-5-phenoxypyrimidin 
• 118643-87-1 2-Amino-4,6-dichlor-5-phenoxypyrimidin 

Relevant articles and documents

Cross dehydrogenative C-O coupling catalysed by a catenane-coordinated copper(i)

Catalytic activity of copper(i) complexes supported by phenanthroline-containing catenane ligands towards a new C(sp3)-O dehydrogenative cross-coupling of phenols and bromodicarbonyls is reported. As the phenanthrolines are interlocked by the strong and flexible mechanical bond in the catenane, the active catalyst with an open copper coordination site can be revealed only transiently and the stable, coordinatively saturated Cu(i) pre-catalyst is quickly regenerated after substrate transformation. Compared with a control Cu(i) complex supported by non-interlocked phenanthrolines, the catenane-supported Cu(i) is highly efficient with a broad substrate scope, and can be applied in gram-scale transformations without a significant loss of the catalytic activity. This work demonstrates the advantages of the catenane ligands that provide a dynamic and responsive copper coordination sphere, highlighting the potential of the mechanical bond as a design element in transition metal catalyst development.

Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals

Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O) 2 NR 1 R 2 ] zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O) 2 NR 1 R 2 groups and is always at least one; R 1 and R 2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.